Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when

doi:10.4254/wjh.121491

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 121491
Published online Aug 27, 2026. doi: 10.4254/wjh.121491

Table 3 Overview of drugs in clinical trials for primary biliary cholangitis

Drug name	Drug class	Therapeutic indication	Study phase
Tropifexor	FXR agonist	PBC	Phase 2 complete
Cilofexor	FXR agonist	PBC	Phase 2 complete
TQA3526	FXR agonist	PBC	Phase 3 ongoing
ASC42	FXR agonist	PBC	Phase 2 closed prematurely
Nor-UDCA	UDCA homolog	PBC	Phase 2 ongoing
Aldafermin	FGF-19 analogue	PBC	Phase 2 complete
Setanaxib	NOX 1/4 inhibitor	PBC	Phase 2b complete
Linerixibat	IBAT inhibitor	Pruritus in PBC	Phase 3 complete; FDA approved for pruritus in PBC
Maralixibat	IBAT inhibitor	Pruritus in PBC	Phase 2 complete
Volixibat	IBAT inhibitor	Pruritus in PBC	Phase 2b ongoing

FDA: Food and drug administration; FGF: Fibroblast growth factor; FXR: Farnesoid X receptor; IBAT: Ileal bile acid transporter; NOX1/4: Dual nicotinamide adenine dinucleotide phosphate oxidase 1/4; PBC: Primary biliary cholangitis; UDCA: Ursodeoxycholic acid.

Full Size Table

Citation: Drazilova S, Jarcuska P, Koky T, Harhovsky M, Komarova S, Vasil J, Janicko M. Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when. World J Hepatol 2026; 18(8): 121491
URL: https://www.wjgnet.com/1948-5182/full/v18/i8/121491.htm
DOI: https://dx.doi.org/10.4254/wjh.121491

Drazilova S, Jarcuska P, Koky T, Harhovsky M, Komarova S, Vasil J, Janicko M. Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when. World J Hepatol 2026; 18(8): 121491 [DOI: 10.4254/wjh.121491]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.